株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ブタクサアレルギー : パイプライン分析

Ragweed Allergy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 255966
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
ブタクサアレルギー : パイプライン分析 Ragweed Allergy - Pipeline Review, H2 2016
出版日: 2016年07月13日 ページ情報: 英文 37 Pages
概要

ブタクサアレルギーとは、ブタクサの花粉がアレルギー体質の人の体内に鼻・のど経由で入り込み、アレルギーや喘息を引き起こすという疾患です。主な症状として、くしゃみや鼻水・鼻づまり、のどや耳内部の痒み、じんましん、目の腫れ・痒みなどが挙げられます。主な治療薬には、鬱血除去薬や抗ヒスタミン剤、鼻用コルチコステロイド剤などがあります。

当レポートでは、世界各国でのブタクサアレルギー治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

ブタクサアレルギーの概要

治療薬の開発

  • ブタクサアレルギー向けパイプライン製品:概要
  • ブタクサアレルギー向けパイプライン製品:比較分析

各企業で開発中のブタクサアレルギー治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

ブタクサアレルギー治療薬:開発中の製品の一覧(企業別)

ブタクサアレルギー治療薬の開発に従事している企業

  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • Immunomic Therapeutics, Inc.
  • Stallergenes S.A.

ブタクサアレルギー:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ブタクサ花粉アレルゲン
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • AllerR
  • BM-34
  • Multi-LAMP-Vax
  • PL-101
  • ブタクサ低アレルギー性ワクチン
  • 喘息、ブタクサアレルギー、鼻結膜炎向けワクチン

ブタクサアレルギー治療薬:パイプライン製品の最新動向

ブタクサアレルギー治療薬:開発が休止状態の製品

ブタクサアレルギー治療薬:開発が中止された製品

ブタクサアレルギー関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8230IDB

Summary

Global Markets Direct's, 'Ragweed Allergy - Pipeline Review, H2 2016', provides an overview of the Ragweed Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy
  • The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ragweed Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ragweed Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Ragweed Allergy - Overview
  • Ragweed Allergy - Therapeutics under Development by Companies
  • Ragweed Allergy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Ragweed Allergy - Products under Development by Companies
  • Ragweed Allergy - Companies Involved in Therapeutics Development
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • Immunomic Therapeutics, Inc.
  • Ragweed Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Multi-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ragweed Allergy - Dormant Projects
  • Ragweed Allergy - Discontinued Products
  • Ragweed Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
      • Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study
      • Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
      • Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
      • Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
      • Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ragweed Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Ragweed Allergy - Pipeline by Anergis SA, H2 2016
  • Ragweed Allergy - Pipeline by Biomay AG, H2 2016
  • Ragweed Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ragweed Allergy - Dormant Projects, H2 2016
  • Ragweed Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ragweed Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top